Меню
Набор скоро начнётся NCT07693894

DISARM Clinical Study B: Evaluation of Innovative Ovarian Cancer Biomarker Assays

— Наблюдательное Ovarian Cancer

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Investigational ovarian cancer biomarker assays.
Кому может быть актуально
Состояния в реестре: Ovarian Cancer. Базовые параметры: от 35 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Multi-site, Multi-country Evaluation of Innovative Ovarian Cancer Biomarker Assays. (DISARM Clinical Study B-CSB)

Обзор

Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes. Recent research has focused on the development of blood-based tests, sometimes referred to as liquid biopsy tests, which aim to look for changes in the blood that could be linked to cancer. These tests are still under investigation and are not part of routine clinical care. The purpose of this study is to evaluate several blood-based ovarian cancer tests. This will be done by comparing test results from people who have ovarian cancer with results from people who do not have cancer. The study will also collect information from standard blood tests and genetic analyses to better understand how these results relate to ovarian cancer. This study is for research purposes only. The blood-based tests being evaluated are investigational and are not used to make medical decisions or diagnoses for women taking part in the study.

Подробное описание

The DISARM Clinical Study B (CSB) is a multisite, multi-country, non-commercial, minimal risk, exploratory research study with a case-control design. The study aims to evaluate the discriminatory abilities of innovative liquid biopsy biomarker assays for ovarian cancer, including glycans/glycoproteins (OVA-GLY), volatile organic compounds (OVA-VOC), and circulating miRNAs (OVA-miRNAs). Primary endpoints are the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity of the investigational biomarker assays.

Women with epithelial ovarian cancer (EOC) before treatment and healthy controls (participants without cancer diagnosis) will be recruited across participating European clinical sites. Subjects presenting with adnexal masses suspicious of ovarian cancer will be enrolled and tested before surgery and retrospectively classified according to histopathological findings. No randomisation, blinding, or interventional procedures are foreseen. The only study-specific procedure is the minimally invasive collection of blood samples.

Вмешательства

  • Диагностический тест Investigational ovarian cancer biomarker assays
    Collection of blood samples for investigational ovarian cancer biomarker analyses (OVA-GLY, OVA-VOC and OVA-miRNA).

Первичные конечные точки

  • To evaluate the discriminatory abilities of the individual biomarker assays (OVA-GLY, OVA-VOC, OVA-miRNA) in distinguishing EOC from non-cancer. [Срок оценки: Baseline]
Вторичные конечные точки (4)
  • To evaluate the discriminatory ability of OVA-Multimodal in distinguishing EOC from non-cancer [Срок оценки: Baseline (single study visit)]
  • To evaluate the discriminatory abilities of the individual biomarker assays (OVA-GLY, OVA-VOC, OVA-miRNA) and OVA-Multimodal in comparison to CA-125. [Срок оценки: Baseline (single study visit)]
  • To estimate the cost-effectiveness of the DISARM assays versus CA-125 under defined clinical-use scenarios using model-based early economic evaluation and study-based resource use and cost data. [Срок оценки: Baseline (single study visit)]
  • To explore and quantify associations between candidate risk factors and EOC case status by comparing EOC cases with healthy controls. [Срок оценки: Baseline (single study visit)]

Критерии участия

Критерии включения

EOC patients

  • Women, trans men and non-binary people with female reproductive organs
  • Aged ≥35 years\*
  • Pathologically diagnosed, by biopsy, with EOC prior to surgical intervention or treatment
  • Presenting with adnexal mass suspicious of OC on imaging and scheduled for surgical resection or biopsy (and subsequent confirmation of EOC)
  • Able to give informed consent

Healthy controls

  • Women, trans men and non-binary people with female reproductive organs
  • Aged ≥35 years
  • No cancer history
  • Able to give informed consent

Критерии исключения

  • Prior history and any treatment for malignancy
  • Prior removal of either ovary for any reason
  • Pregnant or lactating
  • Any condition or circumstance that, in the opinion of the investigator, could interfere with the participant's ability to participate or comply with study requirements

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения
Случай-контроль

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07693894 · DISARM CSB · 101214318

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗